• +1-646-491-9876
    • +91-20-67278686

    Search

    Kaposi Sarcoma-Pipeline Review H1 2017

    Kaposi Sarcoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834333
    • Category Pharmaceuticals
    • No. of Pages 76
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Kaposi Sarcoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2017, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.

    Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Kaposi Sarcoma - Overview
    Kaposi Sarcoma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Kaposi Sarcoma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Kaposi Sarcoma - Companies Involved in Therapeutics Development
    Aphios Corp
    Cannabis Science Inc
    CytRx Corp
    LATITUDE Pharmaceuticals Inc
    RedHill Biopharma Ltd
    Tumorend LLC
    VasGene Therapeutics Inc
    Kaposi Sarcoma - Drug Profiles
    ABC-294640 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aldoxorubicin hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CM-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSTATI-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Dermos - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    doxorubicin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon alfa-2a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon alfa-2b - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TLD-208 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vas-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Kaposi Sarcoma - Dormant Projects
    Kaposi Sarcoma - Discontinued Products
    Kaposi Sarcoma - Product Development Milestones
    Featured News & Press Releases
    Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting
    May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi's Sarcoma Awarded to Navidea
    May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update
    Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016
    Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi's Sarcoma
    Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages
    Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma
    Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
    Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma
    Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma
    Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
    Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
    Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma
    Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Kaposi Sarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Kaposi Sarcoma - Pipeline by Aphios Corp, H1 2017
    Kaposi Sarcoma - Pipeline by Cannabis Science Inc, H1 2017
    Kaposi Sarcoma - Pipeline by CytRx Corp, H1 2017
    Kaposi Sarcoma - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
    Kaposi Sarcoma - Pipeline by RedHill Biopharma Ltd, H1 2017
    Kaposi Sarcoma - Pipeline by Tumorend LLC, H1 2017
    Kaposi Sarcoma - Pipeline by VasGene Therapeutics Inc, H1 2017
    Kaposi Sarcoma - Dormant Projects, H1 2017
    Kaposi Sarcoma - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Kaposi Sarcoma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Kaposi Sarcoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aphios Corp
    Cannabis Science Inc
    CytRx Corp
    LATITUDE Pharmaceuticals Inc
    RedHill Biopharma Ltd
    Tumorend LLC
    VasGene Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//kaposi-sarcoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//kaposi-sarcoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//kaposi-sarcoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments